Clinical Management and Experimental Models of Surfactant-Related Lung Disease

Proceedings of the 17th International Workshop on Surfactant Replacement, Cagliari, May 24–26, 2002

Guest Editors
G. Bevilacqua, Parma
T. Curstedt, Stockholm
H.L. Halliday, Belfast
B. Robertson, Stockholm
O.D. Saugstad, Oslo
C.P. Speer, Würzburg

4 figures and 1 table, 2002
Drug Dosage

The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Contents

1 Preface

2 Lung Lining Liquid – The Hidden Depths. The 5th Nils W. Svenningsen Memorial Lecture
Walters, D.V. (London)

6 Molecular Interactions in Pulmonary Surfactant Films
Pérez-Gil, J. (Madrid)

16 Continuous Positive Airway Pressure and Surfactant; Combined Data from Animal Experiments and Clinical Trials
Thomson, M.A. (London)

20 The Future of Surfactant Therapy for Patients with Acute Lung Injury – New Requirements and New Surfactants
Spragg, R.G. (San Diego, Calif.)

25 The Role of High Frequency Oscillatory Ventilation in Very Preterm Infants
Calvert, S. (London)

28 Surfactant Use in Severe Bronchiolitis. Invited Commentary
Marraro, G.A. (Milan)

29 Abstracts

42 Author and Subject Index